Advocacy at a Glance 12/18/20 Advocacy at a Glance 12/18/20 What Will Actually Get Funded at FDA in FY 21? Read More Analysis and Commentary 10/1/20 Analysis and Commentary 10/1/20 Understanding the Short-Term CR Read More Analysis and Commentary 9/25/20 Analysis and Commentary 9/25/20 How FDA is Funded, ... and Why Read More Advocacy at a Glance 9/25/20 Advocacy at a Glance 9/25/20 Advocacy at a Glance Read More Analysis and Commentary 8/7/20 Analysis and Commentary 8/7/20 CDER Priorities: During the Pandemic and for 2021 Read More Advocacy at a Glance 8/7/20 Advocacy at a Glance 8/7/20 Advocacy at a Glance Read More Analysis and Commentary 8/1/20 Analysis and Commentary 8/1/20 About the Alliance for a Stronger FDA Read More Advocacy at a Glance 3/27/20 Advocacy at a Glance 3/27/20 Advocacy at a Glance Read More Analysis and Commentary 3/13/20 Analysis and Commentary 3/13/20 "Cures," Coronavirus, NDD, and Other Issues for FY 21 Read More 5/10/18 5/10/18 Alliance "Deeply Appreciative" of House's FY 19 Funding Mark Read More Analysis and Commentary 3/16/18 Analysis and Commentary 3/16/18 Key CDER Priorities Need Funding Too Read More Analysis and Commentary 3/11/18 Analysis and Commentary 3/11/18 Game-Changing Medical Device Priorities Need Funding Read More Analysis and Commentary 12/22/17 Analysis and Commentary 12/22/17 From This Week's CR into FY 19: More Alliance Priorities Read More Advocacy at a Glance 12/22/17 Advocacy at a Glance 12/22/17 Advocacy at a Glance Read More Analysis and Commentary 9/29/17 Analysis and Commentary 9/29/17 Plus ça Change, Plus c'est la Même Chose Read More Analysis and Commentary 8/11/17 Analysis and Commentary 8/11/17 It's Going to Get Tougher From Here Read More Advocacy at a Glance 3/17/17 Advocacy at a Glance 3/17/17 Advocacy at a Glance Read More Analysis and Commentary 12/16/16 Analysis and Commentary 12/16/16 Time for a Deep Breath Before the New Year Begins Read More Advocacy at a Glance 10/14/16 Advocacy at a Glance 10/14/16 Advocacy at a Glance Read More Analysis and Commentary 9/23/16 Analysis and Commentary 9/23/16 FDA Purchasing Power is on the Line Read More Older Posts
Advocacy at a Glance 12/18/20 Advocacy at a Glance 12/18/20 What Will Actually Get Funded at FDA in FY 21? Read More
Analysis and Commentary 10/1/20 Analysis and Commentary 10/1/20 Understanding the Short-Term CR Read More
Analysis and Commentary 9/25/20 Analysis and Commentary 9/25/20 How FDA is Funded, ... and Why Read More
Analysis and Commentary 8/7/20 Analysis and Commentary 8/7/20 CDER Priorities: During the Pandemic and for 2021 Read More
Analysis and Commentary 8/1/20 Analysis and Commentary 8/1/20 About the Alliance for a Stronger FDA Read More
Analysis and Commentary 3/13/20 Analysis and Commentary 3/13/20 "Cures," Coronavirus, NDD, and Other Issues for FY 21 Read More
Analysis and Commentary 3/16/18 Analysis and Commentary 3/16/18 Key CDER Priorities Need Funding Too Read More
Analysis and Commentary 3/11/18 Analysis and Commentary 3/11/18 Game-Changing Medical Device Priorities Need Funding Read More
Analysis and Commentary 12/22/17 Analysis and Commentary 12/22/17 From This Week's CR into FY 19: More Alliance Priorities Read More
Analysis and Commentary 9/29/17 Analysis and Commentary 9/29/17 Plus ça Change, Plus c'est la Même Chose Read More
Analysis and Commentary 8/11/17 Analysis and Commentary 8/11/17 It's Going to Get Tougher From Here Read More
Analysis and Commentary 12/16/16 Analysis and Commentary 12/16/16 Time for a Deep Breath Before the New Year Begins Read More
Analysis and Commentary 9/23/16 Analysis and Commentary 9/23/16 FDA Purchasing Power is on the Line Read More
